ELAN Q3 2024 Earnings — Elanco Animal Health Incorporated Revenue & Financial Results | Market Cap Arena

ELANElanco Animal Health Incorporated

$12B

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.0B-3.6% YoY

Gross Profit

$405M39.3% margin

Operating Income

-$5M-0.5% margin

Net Income

$364M35.3% margin

EPS (Diluted)

$0.73

QoQ Revenue Growth

-13.0%

Cash Flow

Operating Cash Flow

$162M

Free Cash Flow

$120M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$13.3B

Total Liabilities

$6.8B

Stockholders' Equity

$6.5B

Cash & Equivalents

$490M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.0B	$1.1B	-3.6%
Gross Profit	$405M	$441M	-8.2%
Operating Income	-$5M	$42M	-111.9%
Net Income	$364M	-$1.1B	+133.2%

Revenue Segments

Farm Animal

$530M34%

Pet Health

$486M31%

Cattle

$253M16%

Poultry

$188M12%

Swine

$88M6%

Contract Manufacturing

$14M1%

Geographic Segments

Non-US

$543M53%

UNITED STATES

$487M47%